Evidence map›Paper›PMID 41685327›Full record

ArticleFrontiers in immunology2026

Phosphatidylserine liposomes for

Tommaso Olimpieri, Noemi Poerio, Fabio Saliu, Nicola I Lorè, Fabiana Ciciriello, Greta Ponsecchi, Federico Alghisi, Daniela M Cirillo, Marco M D'Andrea, Maurizio Fraziano

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tommaso OlimpieriDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Noemi PoerioDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Fabio SaliuEmerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Nicola I LorèEmerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Fabiana CicirielloPneumology and Cystic Fibrosis Unit, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Greta PonsecchiDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Federico AlghisiPneumology and Cystic Fibrosis Unit, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
Daniela M CirilloEmerging Bacteria Pathogens Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, Italy.
Marco M D'AndreaDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Maurizio FrazianoDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously demonstrated that phosphatidylserine liposomes (PS-L) reduce inflammation and enhance intracellular killing of

Indexed as

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorLiposomesMycobacterium abscessusMycobacterium Infections, NontuberculousPhosphatidylserinesAmikacinAnti-Bacterial AgentsCytokinesHost-Directed TherapyHumansMacrophagesAmikacinAnti-Bacterial AgentsCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCytokinesLiposomesPhosphatidylserinescystic fibrosishost-directed therapyinnate immunityliposomesMycobacterium abscessus

Identifiers

PMID41685327
PMCPMC12891076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.